PharmaBiome, a Zurich-based biotechnology company, is pioneering the development of living microbiome therapies to address gut health issues. Utilizing their NicheMap™ technology, they create standardized bacterial consortia targeting diseases linked to microbiome dysbiosis. This approach evolves beyond traditional pharmacology, seeking precise mechanisms and promoting healthier gut ecosystems for improved patient outcomes.
The post Therapeutics Come Alive: An Interview with PharmaBiome appeared